Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Extension Study to Monitor Long-Term Safety of LUM-201 in Children with Idiopathic Growth Hormone Deficiency
2023-504020-25-00Phase 2Authorised
- Sponsor
- Lumos Pharma, Inc.
- Start
- Dec 2023
- Modality
- Small Molecules
- Countries
- 5
01
Overview
Phase 2, open-label, single-arm trial of ibutamoren in idiopathic growth hormone deficiency (I-GHD), sponsored by Lumos Pharma, Inc. Primary endpoint: Safety: occurrence of adverse events and clinical findings. Planned start Dec 2023; status: authorised.
02
Drugs
ibutamoren
03
Conditions
idiopathic growth hormone deficiency (I-GHD)
Beyond the preview
Go deeper on 2023-504020-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-504020-25-00.